" class="no-js "lang="en-US"> The FH Foundation - Medtech Alert
Thursday, September 11, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
The FH Foundation | Pharmtech Focus

The FH Foundation

About The FH Foundation

The FH Foundation

The mission of the FH Foundation is to raise awareness of FH (familial hypercholesterolemia) through education, advocacy, and research. Our goal is to save lives by increasing the rate of early diagnosis and encouraging proactive treatment. If left untreated this life-threatening genetic disorder leads to aggressive cardiovascular disease in men, women, and children.

Related Story

Cardiovascular

 FDA Approves Repatha ® (evolocumab) in Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia | Pharmtech Focus

FDA Approves Repatha ® (evolocumab) in Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia

September 27 2021

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Repatha ® (evolocumab) as an […]